Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$957.00 USD

957.00
547,371

+19.39 (2.07%)

Updated May 3, 2024 04:00 PM ET

After-Market: $958.14 +1.14 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ekta Bagri headshot

3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

Select Medical (SEM) Unveils Separation Plan for Concentra

Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.

Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?

Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Best Momentum Stocks to Buy for January 3rd

SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.

Nalak Das headshot

Top 5 Momentum Picks for January After a Fabulous 2023

We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Counter Market Volatility

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), Kanzhun Limited (BZ) and Stride (LRN) are well-poised to gain.

Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?

Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.

The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK

Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.

Kinjel Shah headshot

5 Big Drug Stocks That May Continue to Outperform in 2024

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

Mark Vickery headshot

Top Analyst Reports for Chevron, SAP & United Parcel Service

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), SAP SE (SAP) and United Parcel Service, Inc. (UPS).

Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate

Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.

Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus

Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.

EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data

EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study

Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.

Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How

Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.

Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?

Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.

HRMY vs. REGN: Which Stock Is the Better Value Option?

HRMY vs. REGN: Which Stock Is the Better Value Option?

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate

The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.

Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update

Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.

Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates

Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.

Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues

Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.